| Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Biomarkers Definitions Working Group, AJ Atkinson Jr, WA Colburn, ... Clinical pharmacology & therapeutics 69 (3), 89-95, 2001 | 7340 | 2001 |
| Physiologically-based pharmacokinetics in drug development and regulatory science M Rowland, C Peck, G Tucker Annual review of pharmacology and toxicology 51, 45-73, 2011 | 663 | 2011 |
| Systems and methods for monitoring health and delivering drugs transdermally JF Currie, M Paranjape, CC Peck, R White, TW Schneider US Patent 6,887,202, 2005 | 489* | 2005 |
| Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems DA Kessler, S Natanblut, D Kennedy, E Lazar, P Rheinstein, C Anello, ... Jama 269 (21), 2765-2768, 1993 | 452 | 1993 |
| Simulation of clinical trials NHG Holford, HC Kimko, JPR Monteleone, CC Peck Annual review of pharmacology and toxicology 40 (1), 209-234, 2000 | 347 | 2000 |
| Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development C Peck Carl, Z Benet Leslie, E Robert, G John, H Rodman John, J Jerome, ... Clin. Pharmacol. Ther. 51, 465-474, 1992 | 307 | 1992 |
| Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans LJ Lesko, M Rowland, CC Peck, TF Blaschke The Journal of Clinical Pharmacology 40 (8), 803-814, 2000 | 231 | 2000 |
| Transdermal detection system CC Peck US Patent 4,821,733, 1989 | 207 | 1989 |
| Extended least squares nonlinear regression: a possible solution to the “choice of weights” problem in analysis of individual pharmacokinetic data CC Peck, SL Beal, LB Sheiner, AI Nichols Journal of Pharmacokinetics and Biopharmaceutics 12 (5), 545-558, 1984 | 203 | 1984 |
| Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29–30, 2002) M Rowland, L Balant, C Peck AAPS PharmSci 6, 56-67, 2004 | 169 | 2004 |
| Toxic potential of the plasticizer Di (2-ethylhexyl) phthalate in the context of its disposition and metabolism in primates and man. CC Peck, PW Albro Environmental health perspectives 45, 11-17, 1982 | 166 | 1982 |
| Postmarketing drug dosage changes of 499 FDA‐approved new molecular entities, 1980–1999 J Cross, H Lee, A Westelinck, J Nelson, C Grudzinskas, C Peck Pharmacoepidemiology and drug safety 11 (6), 439-446, 2002 | 161 | 2002 |
| An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development: experience within Hoffmann La Roche BG Reigner, PEO Williams, IH Patel, JL Steimer, C Peck, ... Clinical pharmacokinetics 33, 142-152, 1997 | 146 | 1997 |
| Computer-assisted digoxin therapy CC Peck, LB Sheiner, CM Martin, DT Combs, KL Melmon New England Journal of Medicine 289 (9), 441-446, 1973 | 145 | 1973 |
| Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis H Lee, HC Kimko, M Rogge, D Wang, I Nestorov, CC Peck Clinical Pharmacology & Therapeutics 73 (4), 348-365, 2003 | 141 | 2003 |
| Understanding consequences of concurrent therapies CC Peck, R Temple, JM Collins Jama 269 (12), 1550-1552, 1993 | 135 | 1993 |
| Improved computer-assisted digoxin therapy: a method using feedback of measured serum digoxin concentrations LB SHEINER, H HALKIN, C PECK, B ROSENBERG, KL MELMON Annals of Internal Medicine 82 (5), 619-627, 1975 | 132 | 1975 |
| Dermal substance collection device CC Peck US Patent 4,706,676, 1987 | 131 | 1987 |
| The randomized concentration-controlled trial: an evaluation of its sample size efficiency LP Sanathanan, CC Peck Controlled clinical trials 12 (6), 780-794, 1991 | 119 | 1991 |
| Appraisal of hemoglobin solution as a blood substitute. F DeVenuto, HI Friedman, JR Neville, CC Peck Surgery, Gynecology & Obstetrics 149 (3), 417-436, 1979 | 119 | 1979 |
